7 news items
Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
CYTK
22 May 24
cost of capital as we become a sustainable company. We believe this deal delivers on stated objectives of advancing our later-stage portfolio
Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
CYTK
22 May 24
capital structure and lowering our cost of capital as we become a sustainable company. We believe this deal delivers on stated objectives of advancing our
Cytokinetics Announces Primary Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress and Published in the New England Journal of Medicine
CYTK
13 May 24
Subgroups Rapid and Sustained Improvements Observed in Symptoms and Function; No Treatment
Cytokinetics Reports First Quarter 2024 Financial Results
CYTK
8 May 24
, Research Evaluation of Sustained Treatment with Aficamten in HCM
Omega Therapeutics, Inc. Reports Q1 Loss, Tops Revenue Estimates
CYTK
OMGA
6 May 24
.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations
vouth2steq29k5mdec
CYTK
5 Apr 24
and sustained reductions in left ventricle outflow tract gradient (LVOT-G), and improvements in symptoms and cardiac biomarkers. The updated data set
zbn er64y3153ufpffdnuavqrysuj4ggzkg52w4yynj20f
CYTK
5 Apr 24
Evaluation of Sustained Treatment with Aficamten in HCM), the open label
- Prev
- 1
- Next